ELEVATE-HFpEF Clinical Study
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
- Study ID
- NCT06678841
- Status
- Recruiting
Conditions
- Heart Failure With Preserved Ejection Fraction (HFpEF)
Eligibility Criteria
- Sex
- ALL
- Age
- 40 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Personalized cardiac pacing — DEVICEPersonalized cardiac pacing treatment based each patient's height and baseline LVEF.
Study Details
ELEVATE-HFpEF is a prospective, randomized, controlled, double-blinded, multi-center, global, interventional pivotal study evaluating the safety and efficacy of dual chamber personalized pacing compared to minimal or no pacing for the treatment of patients with heart failure with preserved ejection fraction (HFpEF).
Key Dates
- Start date
- Jul 9, 2025
- Status verified
- May 2026
- Primary completion
- Aug 31, 2028
- Completion
- Feb 28, 2029
Study Design
- Enrollment
- 700 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Personalized Pacing Therapy (Treatment Group)The treatment group will receive a qualifying Medtronic dual chamber pacemaker limited to Astra XT or Azure XT and programmed to provide dual chamber pacing at a personalized cardiac pacing rate determined by patient height and baseline LVEF percentage.
- No Intervention: Control GroupThe control group will receive a qualifying Medtronic dual chamber pacemaker limited to Astra XT or Azure XT and programmed to provide ventricular pacing at a non-personalized rate. This is considered limited or backup pacing.
Primary Outcome Measure
Primary Efficacy Objective: Hierarchical composite endpoint of cardiovascular mortality, urgent HF events, HF events requiring an oral diuretic intensification (ODI), change in KCCQ, change in six-minute walk test distance, and change in NT-proBNP. [ Time Frame: Follow-up duration for endpoint analysis is 12-months. ]
Central Contacts
- Dawn Dyer954-682-8334
Locations (25)
Find similar trials in Phoenix, AZ
Related Studies
- Women's Ischemia Syndrome Evaluation (WISE) Pre-HFpEFRecruiting · Cedars-Sinai Medical Center · Los Angeles, California
- Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection FractionPHASE2 · Enrolling By Invitation · Mayo Clinic · Rochester, Minnesota
- Study in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)PHASE1 · Recruiting · Secretome Therapeutics · Chicago, Illinois
- The Effect of Adiposity on Muscle and Microvascular Function in HFpEFEnrolling By Invitation · University of Texas Southwestern Medical Center · Dallas, Texas